Identifying research for the study of drug-related PML

On the 25th and 26th of July EFA President Breda Flood attended a European Medicines Agency (EMA) workshop on reducing the burden of drug-related progressive multifocal leukoencephalopathy (PML), a rare, debilitating and sometimes fatal disease that has been identified as an adverse drug reaction to some medicines that affect immunological functions, despite the fact that other medicines associated with PML can bring major benefits. More information

Leave a Reply

EFA eZine Archive